Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

Completed · Phase 1/Phase 2

Conditions studied: Geographic Atrophy, Age-Related Macular Degeneration

In brief

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30. Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit 2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection, week 17, week 26. Exams will look for continuous changes in visual acuity, change in area of geographic atrophy lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in reading speed, and change in microperimetry response.

Key facts

Study ID

NCT06164587

Run by

Inflammasome Therapeutics

People needed

30

Starts

2024-04-18

Expected to finish

2026-05-15

Last updated by the study team

2026-07-20

Who can join

Age: 50 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 50 or older, diagnosed with geographic atrophy (GA) due to age-related macular degeneration (AMD).
• Best corrected visual acuity (BCVA) 24 or greater Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (approximately Snellen 20/320 or greater), in study eye.
• The entire geographic atrophy (GA) lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy except in such cases where there is a "neck" or some narrow area connecting the GA with the peripapillary atrophy, as determined by Fundus Autofluorescence (FAF) imaging at screening:
• Both eyes must have GA and the total GA area in each eye must be ≥ 2.5 and ≤ 20.0 mm2 (1 and 8 disk areas [DA] respectively)
• If geographic atrophy (GA) is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA), with the overall aggregate area of GA, as specified above.
• If geographic atrophy (GA) is unifocal, then the lesion must be extrafoveal.
• Presence of any pattern of hyperautofluorescence in the junctional zone of geographic atrophy (GA). Absence of hyperautofluorescence (i.e., pattern = none) is exclusionary.
• Fundus Autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT), or Fluorescein Angiography (FA) imaging of entire geographic atrophy (GA)lesion at least 6 months prior to entry.
• General Exclusion Criteria:
• Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception
• History or current evidence of hypersensitivity to any components of the study medication or fluorescein, as assessed by the investigator
• Participation in any investigational drug or device study within 30 days prior to baseline
• History or current evidence of a medical condition or medication use that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study
• Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
• Ocular Exclusion Criteria:
• Active ocular or periocular infections, malignancy
• History of major ophthalmic surgery in the past 3 months, and any ophthalmic surgery in study eye in the last 30 days
• History of significant ocular disease other than AMD that may confound results
• Any history or current evidence of exudative ("wet") AMD including any evidence of retinal pigment epithelium rips or evidence of retinal, choroidal, or peripapillary neovascularization in either eye
• Known hypersensitivity to study drug or any of the excipients in implant
• Macular atrophy secondary to a condition other than AMD
• History of laser therapy in the macular region
• Aphakia or surgically compromised/absent posterior capsule including presence of scleral fixated lenses. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary
• History of prior posterior vitrectomy
• History of prior intraocular gene therapy for any indication

Where it is running

• Loma Linda University — Loma Linda, California, United States
• University of Kentucky Advanced Eye Care — Lexington, Kentucky, United States
• The Maine Eye Center — Portland, Maine, United States
• Oregon Eye Consultants, Cascade Medical Research — Eugene, Oregon, United States
• Hilton Head Retina Institute — Hilton Head, South Carolina, United States
• Ophthalmology LTD — Sioux Falls, South Dakota, United States
• Southeastern Retina Associates — Hixson, Tennessee, United States
• Southeastern Retina Associates — Bristol, Virginia, United States
• Vistar Eye Center — Roanoke, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.